Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
at the end of the study
Brendza KM
genetic and cell biology data point to Dyrk1a as the key molecular target
GCN5 and GNAT
2000 Jan 14
TAK-063 Size:Solid 10 mg at the end of theTAK 063, also known as Balipodect., is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. TAK 063 is currently being evaluated in clinical trials for the treatment of schizophrenia. Phosphodiesterase 10A (PDE10A) is a cAMP cGMP phosphodiesterase highly expressed in medium spiny neurons (MSNs) in the striatum. TAK 063 represents a promising drug for the treatment of schizophrenia with potential for superior safety
US$ 31844.50
Sold : Login>>